From: Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study
Number of additional medicationsa
Number (%) patientsb
Aged 41–50 years(n = 161)
Aged > 50 years(n = 85)
1
46 (28.6 %)
12 (14.1 %)
2–3
63 (39.1 %)
38 (44.7 %)
≥4
52 (32.3 %)
35 (41.2 %)